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Bone-marrow mesenchymal stem cells (BM-MSCs) are multipotent self-renewal adult cells with potential to regenerate the damaged tissues in 
degenerative diseases such as osteoarthritis (OA). Nevertheless, research require in vitro expansion of BM-MSCs, a process which eventually causes cell 
senescence. To overcome this problem cell lines can be used but, currently, BM-MSC lines available are scarce and present limitations regarding their 
differentiation capacities. For this reason, the aim of this study was to generate and characterize human BM-MSCs lines, derived from an OA patient and a 
healthy donor, with high chondrogenic and osteogenic capacities for their use in research on Regenerative Medicine for OA. 
We have obtained two SV40LT-transduced human BM-MSC lines: one derived from an OA patient and 
the other derived from a healthy donor. SV40LT nuclear expression was proven in both lines (Figure 
2). A constant increase in PDL values confirms that BM-MSCs lines do not senesce, unlike primary 
BM-MSCs (Figure 3). Expression of CD29, CD44, CD73, CD90 and CD105 and lack of CD34 and CD45 
was conserved in OA BM-MSCs line (Figure 4). Although SV40LT-transduced BM-MSCs maintain their 
multipotency (osteogenic, chondrogenic and adipogenic differentiation capacity), differentiation 
potential was altered after SV40LT transduction. Osteogenic potential was increased while 
adipogenic potential was reduced in BM-MSCs lines (Figure 5). Both BM-MSCs lines showed 
chondrogenic potential and were capable of spheroid formation (Figure 6). 
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Figure 5. Alizarin Red and Oil 
Red O hystochemical stainings 
of osteogenic and adipogenic 
cell differentation experiments. 
For the generation of BM-MSC lines, SV40 large 
T antigen (SV40LT) was used. We developed a 
method for human BM-MSCs transduction 
employing ΦNX-A-produced retroviruses, 
spinoculation with addition of Polybrene and 
transgene expression induction by valproic 
acid (VA) (Figure 1). After antibiotic selection, 
nuclear expression of SV40LT was proven by 
immunocytochemistry. Population doubling 
level (PDL) values were calculated at each 
passage as a measure of proliferation of 
SV40LT-transduced BM-MSCs. Maintenance of 
BM-MSCs characteristics in SV40LT-transduced 
BM-MSCs was proven by analysis of clusters of 
differentiation expression by flow cytometry 
and cell differentiation experiments. Osteogenic 
and adipogenic differentiations were analyzed 
by Alizarin Red and Oil Red O hystochemical 
staining. Chondrogenic differentiation was 
analyzed by Safranin O and Masson’s trichrome 
hystochemical stainings and also by 
immunohystochemical stainings for aggrecan 
and type II collagen. 
Two BM-MSCs lines were generated: one “OA” and one “healthy”. BM-MSC lines shows an increased lifespan while maintaining primary BM-MSCs 
characteristics, although differentiation potential could be altered. Osteogenic potential may be increased by SV40LT transduction. The cell lines 
generated are expected to be very useful in research on Regenerative Medicine for OA. 
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Figure 2. OA BM-MSC line (a) and healthy BM-MSC line (b) 
SV40LT immunocytochemistry. 
Figure 3. Number of generations 
calculated as (log Nf – log Ni) / log 2, being 
Nf the final cell population, Ni the number 
of cells in the inoculum and log the natural 
logarithm  facing days in culture. 
PURPOSE 
Figure 1. Human BM-MSCs transduction method, 
employing SV40LT, ΦNX-A-produced retroviruses, 
spinoculation with Polybrene and addition of  VA. 
1. Plasmid isolation 
-pBABE-puro-SV40LT 
2. ΦNX-A transfection 
3. Retrovirus production 
4. BM-MSCs transduction 
5. Spinoculation with Polybrene 
6. Transgene expression induction with VA 
 
 
 
CD29 CD44 CD73 CD90 CD105 CD34 CD45 
OA BM-MSCs 99,2 99,6 98,4 94,9 85,2 9,9 0,1 
OA MSC line 99,0 98,9 96,2 99,1 82,3 1,5 0,4 
R² = 0,997 
R² = 0,960 
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Figure 4. OA BM-MSCs and OA BM-MSC positive (CD29, 
CD44, CD73, CD90 and CD105) and negative (CD34 and 
CD45) mesenchymal superficial markers expression. 
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Figure 6. Safranin O and 
Masson’s Trichrome 
hystochemical satianings and 
immunohystochemistry against 
aggrecan and type II collagen 
of shperoid-shaped 
chondrogenesis differentiation 
experiments for OA and healty 
MSC lines. 
